Facebook
Twitter
LinkedIn
ForwardCOVID-19 Rapid Clinical Updates: Cardiovascular Complications & Staging, Progression, and Current Management of COVID
In this third in our COVID-19: Keeping Up with a Moving Target series, our experts will discuss the most recent updates on current therapies and their efficacy. In this session, we will be examining the staging, progression, and current management of COVID. This session will also address Cardiovascular Complications of COVID-19. Our experts will also highlight patient cases and discuss audience questions to explore this topic.
Moderators:
Jose Mercado, MD
Ramesh Adhikari, MD FHM, SFHM
Panelists:
Ebrahim Barkoudah, MD, MPH FACP SFHM
Paul G. Auwaerter, MD, MBA, FIDSA
William Garneau, MD, MPH
This activity was made possible in part by an educational grant from Gilead Sciences, Inc.
Target Audience
This activity is designed for hospitalists and front line clinicians working working with COVID-19 patients.
Learning Objectives
- Evaluate current guidance for treatment of COVID-19 patients requiring hospitalization
- Review COVID-19 hospitalization trends in the US
- Discuss findings from randomized clinical trials for treatments in hospitalized COVID-19 patients
- Understand recent recommendations regarding the diagnosis and prevention of VTE in hospitalized adult COVID-19 patients
Ebrahim Barkoudah, MD, MPH FACP SFHM
- Research support payments from: National Institutes of Health/National Heart, Lung, and Blood Institute, Bristol Myers Squibb and Janssen
- Payments made to Brigham and Women's Hospital for performing clinical endpoints sponsored by various entities
- Advisory Board fees: from Bristol Myers Squibb, Janssen, Novartis, Pfizer, and Portola/Alexion.
Paul Auwaerter, MD, MBA, FIDSA
- JNJ: Ownership equity
- Scientific Consulting: Verily, EMD Serono
- DMSB: Humanigen
William Garneau, MD, MPH
- Stock investments in AstraZeneca, Johnson & Johnson
Remaining faculty had no relevant financial or advisory relationships with corporate organizations related to this activity.
SHM CONFLICT OF INTEREST DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, SHM requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. SHM mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. All relevant financial relationships shall be disclosed to participants prior to the start of the activity.
Furthermore, SHM seeks to verify that all scientific research referred to, reported, or used in a continuing medical education (CME) activity conforms to the generally accepted standards of experimental design, data collection, and analysis. SHM is committed to providing its learners with high-quality CME activities that promote improvements in healthcare and not those of a commercial interest.
This activity was made possible in part by an educational grant from Gilead Sciences, Inc.
The Society of Hospital Medicine designates this live activity, for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity
The Society of Hospital Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provider continuing medical education for physicians.
SHM is dedicated to promoting the highest quality care for all hospitalized patients. SHM is committed to promoting excellence in the practice of hospital medicine through education, advocacy and research.
This activity was made possible in part by an educational grant from Gilead Sciences, Inc.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-physician